Global Fibromyalgia Syndrome Market

1. Summary

The Global Fibromyalgia Syndrome Market was valued at $3.0 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 5.2% CAGR, to an estimated market size of $3.8 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The global fibromyalgia syndrome market encompasses pharmaceutical medications (including anticonvulsants, antidepressants, analgesics, and muscle relaxants) and non-pharmacological interventions (such as physical therapy, cognitive behavioral therapy, and digital therapeutics) specifically indicated for the management of chronic widespread pain, fatigue, and cognitive dysfunction. The scope excludes general-purpose analgesics not prescribed for fibromyalgia-specific symptom clusters.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Fibromyalgia Syndrome Market in the period 2025-30:

• Increasing clinical recognition and diagnostic accuracy are expanding the treated patient population globally.
• The market is shifting toward multimodal pain management that integrates pharmacological treatments with behavioral and physical therapies.
• Rapid adoption of digital therapeutics and wearable neuromodulation devices is providing non-invasive alternatives to traditional drugs.
• Development of personalized medicine protocols is allowing for symptom-specific targeting of pain, fatigue, and sleep disturbances.
• Recent regulatory approvals of novel therapies, such as sublingual cyclobenzaprine, are revitalizing a previously stagnant drug pipeline.
• The expansion of online pharmacies and telehealth is improving access to long-term symptom management and medication adherence.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: